NCT06152523View on ClinicalTrials.gov

Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
MSIdMMR Colorectal Cancer
Interventions
DRUG

Monalizumab/MEDI5257

Phase II trial using an A'Hern design with a safety lead-in cohort to assess the safety/tolerability of the combination of monalizumab and MEDI5752 in patients with metastatic MSI/dMMR cancer

Trial Locations (1)

75012

Department of medical oncology - Saint-Antoine Hospital, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06152523 - Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer | Biotech Hunter | Biotech Hunter